{
  "nct_id": "NCT42506814",
  "indication": "Parkinson's Disease",
  "phase": "Phase 1/2",
  "sample_size": 130,
  "duration_weeks": 91,
  "dropout_rate": 0.23,
  "primary_endpoints": [
    "PDQ-39 score"
  ],
  "secondary_endpoints": [
    "PDQ-39 score",
    "OFF time reduction"
  ],
  "blinding": "double-blind",
  "control_arm": "active comparator",
  "outcome_summary": "Study no significant difference compared to placebo.",
  "success": false,
  "failure_reason": "Dosing limitations due to side effects"
}